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ABSTRACT 
Endoscopic variceal ligation plus beta-blockers (EVL+BB) is currently recommended 
for variceal rebleeding prophylaxis, a recommendation that extends to all patients with 
cirrhosis with previous variceal bleeding irrespective of prognostic stage.  
Individualizing patient care is relevant and, in published studies on variceal rebleeding 
prophylaxis, there is a lack of information regarding response to therapy by prognostic 
stage. This study aimed at comparing EVL plus BB with monotherapy (EVL or BB) on 
all-source rebleeding and mortality in patients with cirrhosis and previous variceal 
bleeding stratified by cirrhosis severity (Child A vs. B/C) by means of individual time-
to-event patient data meta-analysis (IPD) from randomized controlled trials. The study 
was IPD of 389 patients from 3 trials comparing EVL plus BB vs. BB and 416 patients 
from 4 trials comparing EVL plus BB vs. EVL. Compared with BB alone, EVL plus BB 
reduced overall rebleeding in Child A (incidence rate ratio 0.40; 95%CI 0.18-0.89; 
p=0.025), but not in Child B/C, without differences in mortality. The effect of EVL on 
rebleeding was different according to Child (p for interaction <0.001). Conversely, 
compared with EVL, EVL plus BB reduced rebleeding in both Child A and B/C, with a 
significant reduction in mortality in Child B/C (incidence rate ratio 0.46; 95%CI 0.25-
0.85; p=0.013). Conclusion: Outcomes of therapies to prevent variceal rebleeding differ 
depending on cirrhosis severity. In patients with preserved liver function (Child A), 
combination therapy is recommended since it is more effective in preventing rebleeding, 
without modifying survival. In patients with advanced liver failure (Child B/C), EVL 
alone carries an increased risk of rebleeding and death as compared with combination 
therapy, underlining that BB is the key element of combination therapy.  
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Preventing recurrent variceal hemorrhage in patients with cirrhosis that have recovered 
from an episode of acute variceal hemorrhage is essential, because otherwise the 1-year 
rebleeding and mortality rates are unacceptably high, at 60% and 30% respectively (1). 
The current standard of care for the prevention of rebleeding is the combination of 
endoscopic variceal ligation (EVL) and non-selective beta-blockers (BB) (2, 3). This 
recommendation is supported by several meta-analyses that have pooled trials 
comparing combination therapy versus monotherapy (BB or EVL alone) (4-6). These 
meta-analyses uniformly concluded that combination therapy had greater efficacy in 
preventing recurrent variceal hemorrhage than either therapy alone, but this benefit did 
not translate into an improved survival. 
However, because studies included in these meta-analyses did not report results by 
prognostic stage, this recommendation is extended to all patients with cirrhosis with a 
previous variceal bleeding, irrespective of cirrhosis stage. Cirrhosis is classified in two 
main prognostic stages: compensated and decompensated (7, 8) and the Child-Turcotte-
Pugh (Child) classification is excellent at stratifying patients with cirrhosis (9), with 
Child A patients being mostly compensated and Child B/C patients being 
decompensated. Additionally, obtaining individual patient data (IPD) allows the 
performance of survival analysis as a time-dependent variable, which was not possible 
in published aggregate data meta-analyses on this topic. 
Therefore, we performed a meta-analysis using IPD obtained from principal 
investigators of randomized controlled trials that compared combination therapy (EVL 
plus BB) versus monotherapy (EVL or BB) with the objective of comparing these 
strategies with regard to time-dependent rebleeding and mortality based on the stage of 
cirrhosis at the time of variceal hemorrhage using the Child-Turcotte-Pugh 
classification. 
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We hypothesized that the impact of each therapy, EVL or BB, on outcomes (rebleeding, 
mortality) would differ according to the severity of cirrhosis. This would be clinically 
relevant as risk stratification would allow tailoring therapy in accordance to patient 
characteristics. In the specific case of BB, it could provide information regarding their 
effect on outcomes in the two main stages of cirrhosis. 
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MATERIAL AND METHODS 
The current meta-analysis was designed to pool the data of individual patients 
participating in randomized controlled trials that compared the efficacy of combination 
therapy (EVL plus BB) versus either therapy alone (EVL or BB) in preventing recurrent 
variceal hemorrhage vis-à-vis the two main prognostic stages of cirrhosis. We searched 
and identified the trials according to previously defined outcomes, revised the data and 
planned statistical analysis. To report the present review, we have adhered to the 
PRISMA-IPD guidelines for reporting meta-analysis of IPD (10). 
Eligibility criteria 
Studies that included patients with cirrhosis undergoing prevention of recurrent 
esophageal variceal hemorrhage were included in this analysis if they were published as 
full articles, if patients were randomly allocated to receive the combination of EVL plus 
BB versus either EVL or BB alone, if information regarding overall rebleeding and 
death was available, and if the original datasets of the trials were available. 
Identifying studies, information sources and search 
We performed a literature search up to December 30, 2015 in MEDLINE, EMBASE, 
the Cochrane Central Register of Controlled trials and the Cochrane Database of 
Systematic Reviews, using the terms rebleeding, recurrent hemorrhage, esophageal 
varices, variceal obliteration, beta-blockers, endoscopy, band ligation and cirrhosis. We 
also reviewed publications in personal reference lists and citation sections of the 
recovered articles; manually searched abstracts presented at meetings of the American 
Gastroenterological Association, the American Association for the Study of Liver 
Diseases, the European Association for the Study of the Liver, the American Society of 
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Gastrointestinal Endoscopy, and the British Society of Gastroenterology and looked at 
authors of the abstracts to identify whether these abstracts had been published in full. 
Finally, we also searched clinical trials at www.controlled-trials.com and 
www.clinicaltrials.gov.   
Study selection and data collection processes 
Two reviewers independently selected the studies by screening the titles and abstracts to 
identify those that fulfilled the inclusion criteria (JM, AA). Principal investigators of the 
trials that met eligibility criteria were contacted to obtain individual patient data for all 
participants in their trials. 
The original datasets were checked for completeness and internal consistency and 
amended through correspondence with the principal investigators. To build the final 
dataset of IPD, we excluded studies with insufficient information, and those that could 
not be obtained upon request.  
Data items 
Patient-level data were analyzed by two authors (JM and DA). The following data were 
extracted from the datasets: patient characteristics (age, sex, etiology of cirrhosis, serum 
bilirubin, serum albumin, prothrombin time, Child-Turcotte-Pugh (Child) class (11), 
presence of ascites or encephalopathy, outcomes (all-source rebleeding, variceal 
rebleeding and mortality), and follow-up (time-to-event for each outcome). Careful 
initial evaluation was performed to ensure completeness of data, and to check 
consistency of the results of the primary analyses for each trial with published reports. 
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Outcomes  
Primary end-points were all-source rebleeding and mortality, and secondary end-point 
was variceal rebleeding. As described by the principal investigators of the included 
trials, all-source and variceal rebleeding were defined as the presence of melena or 
hematemesis with an upper gastrointestinal or an esophageal variceal source, 
respectively, identified by emergency endoscopy after randomization. All-source 
rebleeding was chosen as a primary outcome because EVL may reduce the risk for 
variceal hemorrhage but can also cause bleeding from esophageal ulcers, leaving the 
number of bleeding events per patient unchanged. Mortality was defined as death from 
any cause. The rate of adverse events was also explored. 
Statistical analysis 
The main analysis was a one-stage IPD meta-analysis comparing time-to-event data. 
This utilizes the raw data from each study and allows for adjustments for confounders 
and tests for interactions. Since traditional meta-analysis models are not suited to 
analyze individual time-to-event patient data, multilevel Poisson mixed-effects model 
with random intercepts was used to model time-to-event data that are clustered within 
studies. In the Multilevel Poisson mixed-effects model, the effect of interventions is 
estimated as hazard ratio approximated by incidence rate-ratios (IRR). This approach 
models survival with a fixed treatment effect and a different baseline hazard function 
for each study. So, the assumption of proportional hazards for all studies is relaxed, 
while still assuming proportional hazards between treatment groups within each study 
(12). The effect of intervention was stratified by the severity of cirrhosis, as assessed by 
Child class (A versus B/C). We specifically checked for the modifier effect of Child on 
the interventions by including interaction terms in the models. A significant interaction 
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would indicate that treatment effect was different between Child A and Child B/C 
patients. 
Within each stratum, the model was further adjusted by including the following 
confounders: etiology (alcohol vs. viral vs. others), ascites (presence vs. absence), 
encephalopathy (presence vs. absence), and the continuous variables age, bilirubin and 
albumin. Prothrombin time was not included because of the variability in expressing the 
result of this variable among the trials (prothrombin time in some trials, prothrombin 
activity in others). Inclusion of confounders allows fine tuning of the model within each 
stratum as compared with the coarse adjustment using Child as the sole category. A 
covariate was considered a confounder factor if the difference between adjusted and 
unadjusted model coefficient for the intervention variables varied >10%. In such a case, 
the IRR was shown along with the list of confounders used for adjustment. Otherwise, 
we reported the model without adjustment for confounders. Heterogeneity among trials 
was measured with the random effect parameters of the model, transformed into Median 
Incidence Rate Ratios (MIRR). The MIRR shows the extent by which the probability of 
the event is determined by the trial in which the patients were recruited. The closer the 
MIRR to 1 the lower the variability of the individual risk of an event among trials (13).  
We performed two meta-analyses: The first explored trials that compared combination 
therapy versus BB alone (control group), while the second explored trials that compared 
combination therapy versus EVL alone (control group).  
We carried out sensitivity analysis to verify the robustness of our results on all-source 
and variceal rebleeding. First, we considered death as a competing event for rebleeding, 
and we performed a competing risk analysis including study as a covariate. Secondly, 
we tested, using logistic multilevel regression the impact of including all the patients 
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into the analysis of rebleeding, even those patients excluded from the main analysis 
because they lacked information on time-to-event. Finally, we performed a post-hoc 
exploratory analysis of the effect of the association of BB with ISMN in those four trials 
that compared pharmacological therapy and EVL versus EVL alone, two of which used 
BB alone as pharmacological therapy while the other two used BB with ISMN.  
All analyses were done with Stata v13 (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP) and “xtmepoisson” command. 
 
RESULTS 
Study selection  
Our search strategy identified 798 potential references. We excluded 792 references: 
771 because they were clearly ineligible by reading the title and the abstract and 17 
because of duplicity (Figure 1). Four additional studies were also excluded: Two of 
them because they were in abstract form only and data could not be obtained from the 
authors (14, 15); another because its primary end-point was the incidence and natural 
history of portal hypertensive gastropathy in patients with previous variceal bleeding 
treated with EVL or BB (16; and the last one because it used the HVPG response to BB 
to allocate patients to combination therapy or BB alone, instead of randomly allocating 
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Study characteristics 
Table 1 shows the general characteristics of the 6 studies that met inclusion criteria. All 
the trials, except the one by Ahmad et al., had two study groups that compared the 
combination of EVL and BB versus BB (3 trials) or versus EVL (4 trials). The trial by 
Ahmad et al. compared four groups, BB plus isosorbide-5-mononitrate (ISMN) 
combined with EVL, BB alone, BB plus ISMN, and EVL alone. The specific BB used 
was propranolol in 2 trials (18, 19) and nadolol in 4 trials (20-23), at a dose adjusted to 
reduce resting heart rate by 25% or to 55 bpm (18, 20-22), or to the maximum tolerated 
dose without reducing heart rate below 55 bpm (19, 23). In all studies, BB were started 
within 5 days of the index bleed. BB were associated with ISMN (20 mg bid) in the 
three trials that compared combination therapies with BB alone (18, 22, 23) and in two 
of the four studies that compared combination therapy with EVL alone (18, 19). In one 
of the other two trials, BB were administered together with sucralfate (22). EVL 
sessions were performed with multiband devices in all the trials, and repeated at 
intervals that varied between 10 days and 4 weeks. The mean follow-up of the trials 
varied from 14 to 23 months.  
The Child score was used to assess the severity of cirrhosis in all trials, and the 
publication by Pugh et al. (11) was only referenced in the trial by Lo et al. (21). In all 
trials, rebleeding was considered as such if significant (Table 1). Significant rebleeding 
was defined in all studies except the one by De la Peña et al. (20), by the need to 
transfuse >2 blood units or by a drop in hemoglobin >2 g/dl. De la Peña et al. required a 
drop in hemoglobin to consider rebleeding, but they did not describe the amount (20). 
Supplementary Table 1 shows the methodological quality indices of the included trials 
(24). All trials had an adequate generation of allocation sequence, and adequate 
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allocation concealment. The baseline characteristics of treatment and control groups 
were balanced in all trials. No trial had blinded investigators, only the trial by Kumar et 
al. had a blinded endoscopist (19). The reasons for withdrawal were clear in all trials. 
IPD obtained 
The final IPD dataset was built after excluding patients with insufficient information in 
the original datasets, and in whom data could not be obtained upon request to the 
principal investigators. Supplementary table 2 shows the reasons for and the number 
of patients excluded from the original datasets: 2 lacked Child class (21), 1 lacked any 
clinical information (20), 26 with non-cirrhotic etiology of portal hypertension (19), and 
10 lost to follow-up immediately after randomization and discharge (19). In addition, 
150 patients from Ahmad’s study (18) and 9 patients from Lo’s study (21) were 
excluded from the main analysis, because they lacked information on time-to-event, but 
were included in the analysis of rebleeding using logistic multilevel regression models. 
The dataset from Lo’s study lacked information regarding the source of rebleeding; thus 
120 patients from this study were not included in the analysis of variceal rebleeding 
(22). All patients included in the final dataset had information regarding death. Because 
the studies lacked a uniform standard definitions of adverse events and the information 
reported in the databases was insufficient, we could not perform a safety analysis. 
Patient characteristics 
Characteristics of patients allocated to each treatment group in the 6 included trials are 
shown in Supplementary table 3. The final IPD base was built with 768 patients: 350 
patients allocated to combination of EVL and BB, 206 to EVL alone, and 212 to BB 
alone. Patient characteristics were similar between the combination therapy arms of 
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both sets of trials, and between the combination and the monotherapy arm of each set of 
trials (Table 2).  
Primary outcomes in trials comparing combination therapy (EVL plus BB) versus 
BB alone 
a) All-source rebleeding 
As shown in Figure 2 and Supplementary table 2, 278 patients from two trials were 
used to assess overall rebleeding (22, 23). Fifty-four out of 140 (39%) patients rebled in 
the combination therapy group and 58 out of 138 (42%) patients did in the BB group. 
The IRR (adjusted for etiology, bilirubin and encephalopathy) for overall rebleeding 
was 1.00 (95% CI: 0.68-1.47; p=0.996), that is, there were no differences in rebleeding 
between treatment groups in the overall group.  
Sixty-eight out of the 278 patients were Child A, and 27 of them rebled (40%), 9 on 
combination therapy and 18 on BB. Eighty-five out of 210 Child B/C patients rebled 
(40%), 45 on combination therapy and 40 on BB. Combination of EVL plus BB was 
more effective than BB alone in preventing overall rebleeding in Child A patients (IRR 
0.40; 95% CI: 0.18-0.89; p=0.025), but not in Child B/C patients (IRR, 1.36; 95% CI: 
0.87-2.14; p=0.180) (adjusted for etiology, bilirubin and encephalopathy) (Figure 2). 
This interaction (i.e. difference in response to therapy by Child strata) was statistically 
significant (p=0.009). There was no statistical significant heterogeneity among trials 
(MIRR=1.25; 95%CI: 1.06-2.50; p=0.063). 
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b) Death 
A total of 389 patients from 3 trials were used to assess mortality (Figure 2 and 
Supplementary table 2) (18, 22, 23). Overall, 39 out of 177 (22%) patients on 
combination therapy died compared to 43 out of the 212 (20%) patients on BB. 
Mortality was similar in both study groups [IRR (adjusted for bilirubin and 
encephalopathy) 1.19; 95% CI: 0.76-1.87; p=0.449]. 
Nine out of the 80 Child A patients (11%) died, 2 on combination therapy and 7 on BB, 
whereas 73 out of 309 Child B/C patients died (24%), 37 on combination therapy, and 
36 on BB. Combination of EVL and BB was associated with a lower mortality 
compared to BB alone in Child A patients, although this effect was not statistically 
significant (IRR 0.29; 95% CI: 0.06-1.41; p=0.125). Mortality was greater in Child B/C 
patients on combination therapy than in those on BB, but again the difference was not 
statistically significant (IRR 1.40; 95% CI: 0.87-2.27; p=0.167) (Figure 2). Interaction 
(i.e. difference in response to therapy by Child strata) was not statistically significant 
(p=0.061). There was no statistical significant heterogeneity between trials 
(MIRR=1.25; 95%CI: 1.05-2.64; p=0.137). 
Primary outcomes in trials comparing combination therapy (EVL plus BB) versus 
EVL alone 
a) All-source rebleeding 
As shown in Figure 2 and Supplementary Table 2, a total of 331 patients from 3 trials 
were used to assess overall rebleeding (that is, rebleeding from any source) (19-21). 
Twenty-one of 169 (12%) patients rebled in the combination therapy group compared to 
50 of 162 (31%) patients in the EVL group. The IRR for overall rebleeding was 
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significantly lower in patients in the combination therapy group (IRR 0.36; 95% CI: 
0.21-0.59, p<0.001). 
Ninety-one out of the 331 patients were Child A, and 9 of them rebled (10%), 2 on 
combination therapy and 7 on EVL. Sixty-two out of 240 Child B/C patients rebled 
(26%), 19 on combination therapy and 43 on EVL. Combination of EVL plus BB was 
more effective than EVL alone in preventing overall rebleeding both in Child A (IRR 
0.20; 95% CI: 0.04-0.97; p=0.045) and in Child B/C patients (IRR 0.41; 95% CI: 0.24-
0.70; p=0.001) (Figure 2). The effect of treatment was similar in both strata (p-value for 
the interaction of 0.405). There was no significant heterogeneity (MIRR 1.12; 95%CI: 
1.00-16.56; p=0.357). 
b) Death 
A total of 416 patients from 4 trials contributed to the analysis of mortality (Figure 2 
and Supplementary Table 2) (18-21). Seventeen out of the 210 (8%) patients on 
combination therapy died compared to 33 out of the 206 (16%) patients on EVL, being 
the IRR for mortality of 0.50 (95% CI: 0.28-0.89, p=0.019). Heterogeneity among trials 
was present for this analysis (MIRR=2.16, p<0.001).  
Four out of the 104 Child A patients (4%) died, 2 on combination therapy and 2 on 
EVL, whereas 46 out of 312 Child B/C patients died (15%), 15 on combination therapy, 
and 31 on EVL. Therefore, combination of BB and EVL did not significantly influenced 
mortality in the low-risk Child A patients (IRR 1.11; 95% CI: 0.16-7.93; p=0.915). 
However, in Child B/C patients combination therapy did result in a significant lower 
mortality compared with treatment with EVL alone (IRR 0.46; 95% CI 0.25-0.85; 
p=0.013). Figure 3 shows that the cumulative probability of survival was significantly 
(p<0.01) lower in Child B/C on combination therapy, but not in Child A patients. 
Page 17 of 41
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
RE: Ms HEP-16-2360         18 
Secondary outcome 
Rebleeding from a variceal source was assessed in 278 patients from the trials that 
compared combination therapy versus BB alone (22, 23). Forty-one out of 140 patients 
(29%) rebled from varices in the combination therapy group versus 51 out of 138 
patients in the BB group (37%). The overall IRR (adjusted for bilirubin and 
encephalopathy) for variceal rebleeding was 0.81 (95% CI: 0.53-1.23; p=0.320). When 
stratified by Child, 68 out of the 278 patients were Child A, and 25 of them rebled 
(37%), 7 on combination therapy and 18 on BB therapy. Sixty-seven out of 210 Child 
B/C patients rebled (32%), 34 on combination therapy and 33 on BB. Combination 
therapy (BB plus EVL) was more effective than BB alone in preventing variceal 
rebleeding in Child A patients (IRR 0.26; 95% CI: 0.11-0.61; p=0.002), but not in Child 
B/C patients (IRR 1.24; 95% CI: 0.75-2.05); p=0.410), showing a significant interaction 
(p=0.002). No heterogeneity was detected among trials (MIRR 1.23; 1.05-2.70; 
p=0.109). 
Variceal rebleeding was assessed in 220 patients from the trials that compared 
combination therapy versus EVL alone (19, 20). Twelve out of 115 (10%) patients 
rebled from varices in the combination therapy group versus 18 out of 105 (17%) 
patients in the EVL group. The overall IRR for variceal rebleeding was 0.52 (95% CI: 
0.25-1.11; p=0.091). When stratified by Child, 71 out of the 220 patients were Child A, 
and 4 of them rebled (6%), 1 on combination therapy (25%) and 3 on EVL therapy 
(75%). Twenty-six out of 149 Child B/C patients rebled (17%), 11 on combination 
therapy and 15 on EVL. Therefore, combination of BB and EVL was not more effective 
than EVL in preventing variceal rebleeding either in Child A patients (IRR 0.22; 95% 
CI: 0.02-2.13; p=0.191 or in Child B/C patients (IRR 0.63; 95% CI: 0.28-1.41); 
p=0.264). There was no significant heterogeneity in this analysis (p=0.497).  
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Sensitivity analysis 
We perform two sensitivity analyses for overall and variceal rebleeding, one 
considering death as a competing event and the other including all the patients in the 
analysis, even those without information on time-to-event.  
As shown in Table 3, competing risk regression confirmed the estimates of the main 
analysis.  
In the second sensitivity analysis, we tested whether exclusion of 159 patients from the 
studies by Ahmad et al. and Lo et al. who lacked time-to-event information could have 
biased the results (18, 21). Logistic multilevel regression analyses of all patients with 
information on Child class and treatment outcome independently of time-to-event also 
confirmed the estimates of the model using time-to-event data. The only different result 
was the P value for interaction in the response to EVL by Child strata, which in contrast 
to the main analysis was marginally significant in this analysis (p=0.067) (Table 3).  
Additionally, the post-hoc exploratory analysis in the trials that compared combination 
therapy versus EVL alone showed that compared to EVL alone, trials that used BB 
without ISMN (20, 21) showed a statistically significant (p=0.007) larger impact on 
reducing all-source rebleeding than those trials associating ISMN to BB (18, 19), 
whereas the effect on mortality was not significant (Supplementary table 4) 
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DISCUSSION 
Currently, combination therapy consisting of BB plus EVL is recommended in the 
prevention of recurrent variceal hemorrhage in all patients with cirrhosis who have 
recovered from variceal hemorrhage (2, 3). This recommendation is based on meta-
analyses that have analyzed all patients with cirrhosis, independent of the severity of 
liver disease. Per recent Baveno VI consensus conference and the 2016 Practice 
Guidance by the AASLD on Portal Hypertensive Bleeding in Cirrhosis, risk 
stratification is essential in the treatment of portal hypertension (3, 25). Therefore, the 
objective of our IPD meta-analysis was to determine whether risk stratification would 
identify sub-groups of patients that would benefit the most from combination therapy.  
The current IPD meta-analysis, in addition to increasing the statistical power of 
previous aggregate data meta-analyses, allowed us to examine the effect of combination 
therapy versus monotherapy depending on Child class (A versus B/C) and to analyze 
survival as a time-to-event variable. We elected to stratify patients by Child A versus 
B/C as this would stratify patients in the two main prognostic stages of cirrhosis, 
compensated and decompensated, as most Child A patients are compensated whereas 
the majority of Child B/C patients are decompensated (9). Because trials of combination 
therapy had either BB or EVL as control therapy, we could address the relative 
contribution of BB versus EVL to combination therapy by performing separate meta-
analysis. 
Our meta-analysis included IPD from 389 patients of 3 trials comparing combination 
therapy versus BB and 416 patients of 4 trials comparing combination therapy versus 
EVL.  
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The overall results of our meta-analysis confirm results from aggregate published meta-
analysis (5, 6), that is, that combination therapy is associated with lower rebleeding 
rates when compared to EVL alone but not when compared to BB alone suggesting that 
BB therapy could be sufficient.  It also supports results from aggregate meta-analysis 
demonstrating a lack of effect on mortality of combination therapy versus monotherapy.  
Notably, there was a decrease in mortality with combination therapy in trials where it 
was compared to EVL alone but there was significant heterogeneity among trials and 
therefore this conclusion is not strong. 
Importantly, our meta-analysis showed a different effect of combination therapy in the 
two main stages of cirrhosis.  
In compensated (Child A) patients with cirrhosis, combination therapy (BB plus EVL) 
was clearly associated with lower all-source rebleeding whether it was compared to BB 
alone or to EVL alone but without an effect on mortality.  Lower variceal rebleeding 
rates were observed when combination therapy was compared to EVL alone but not 
when compared to BB alone suggesting that BB therapy could be sufficient. However, 
as recently defined by consensus, the important outcome in a patient who has bled from 
varices is all-source rebleeding, rather than variceal rebleeding (2). 
In decompensated (Child B/C) patients with cirrhosis, combination therapy was 
associated with lower all-source rebleeding rates only in trials where it was compared to 
EVL alone but no significant differences in all-source rebleeding were shown when 
combination therapy was compared to BB alone, suggesting that BB alone could be 
sufficient to prevent all-source rebleeding in this setting.  More importantly, mortality 
was significantly lower only in trials in which combination therapy was compared to 
EVL alone with a tendency for a higher mortality with combination therapy in trials 
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where it was compared to BB alone, suggesting a deleterious effect of EVL on 
mortality.  This deleterious effect was confirmed in time-to-event analysis that, in Child 
B/C patients, showed a significantly higher probability of survival with combination 
therapy when compared to EVL alone. This confirms that, in the setting of 
decompensated cirrhosis, combination therapy actually improves survival and that BB 
use is the key element of combination therapy. The different behavior of EVL according 
to Child class is further supported by the statistically significant interaction between 
both variables on rebleeding. Such a finding is in line with the studies observing an 
inverse relationship between the severity of liver disease and the efficacy of endoscopic 
therapy on rebleeding prevention (26). 
It is likely that BB improve survival in cirrhosis by lowering the rates of rebleeding and 
of other complications of cirrhosis through hemodynamic (reduction in splanchnic 
blood flow, gastroesophageal collateral blood flow and portal pressure) and non-
hemodynamic (reduction in gut bacterial translocation) mechanisms. Since portal 
hypertension and bacterial translocation worsen as cirrhosis progresses to the 
decompensated stage, the benefit of BB on rebleeding and mortality extends through the 
whole spectrum of the disease.  
The absence of impact of BB on mortality in Child A in our study is probably related to 
the very low number of events (deaths) in this population. Alternatively, it can be 
suggested that effective prevention of rebleeding has a limited contribution in 
prolonging survival in initial stages of cirrhosis, and that BB are only able to reduce 
mortality when cirrhosis progresses and the patient is at risk of complications other than 
bleeding. In fact, much of the observed differences in the survival curves between 
patients on combination therapy and those on EVL occurred beyond 18 months, which 
suggests an improvement in the natural history of cirrhosis by BB in the long-term. 
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These results are in agreement with those of Lo et al. who also observed a survival 
benefit of BB independently of rebleeding prevention (27).  
The availability and analysis of a large number of IPD is the main strength of the 
present study. Indeed, obtaining IPD data is a worthy effort. The final database was 
built after a through revision of the original datasets to detect inconsistencies and errors, 
which provided a robust database for analysis on a topic in which new trials with 
current therapies are unlikely. As it is the case in our study, it is commonly 
acknowledged that IPD meta-analysis provides further insights to the estimation of 
treatment effects as compared to more frequently performed aggregate data meta-
analysis (28). Besides, using aggregate data limits the possibility of assessing the impact 
of covariates to trial-level ones. Using IPD overcomes this limitation allowing 
evaluating the impact of patient-level covariates on the estimation of efficacy of 
interventions (29).  Specifically, our IPD meta-analysis has been able to analyze the 
modifier effect of individual patient’s clinical characteristics as the severity of the 
disease (i.e. Child) on the efficacy of combined therapy. This is of importance as the 
severity of liver failure is the main prognostic determinant in patients with cirrhosis 
surviving an episode of variceal bleeding. We have obtained deeper insights on the 
differential effect of the combined therapy depending on individual patient's Child score 
(A vs. B/C). IPD allowed us to perform a multivariate adjustment of the effect of 
combined therapy by other confounders, when needed. So, we can reassure that the 
significant decrease of mortality and rebleeding are not affected by none of the 
covariates included neither by their distribution among the studies. Furthermore, the 
results of our main analysis on all-source and variceal rebleeding were reinforced by 
two sensitivity analyses, a competing risk analysis, considering death as a competing 
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event, and a logistic multilevel regression analysis, including all the patients regardless 
of time-to-event information.  
The association of ISMN to BB in some, but not all trials deserves a comment. ISMN 
was associated to BB in all 3 trials comparing combination therapy (BB and EVL) 
versus BB alone, fact that should be taken into account when considering therapy in this 
context. The effect of pharmacological therapy using BB and ISMN (versus BB) could 
be explored in trials comparing combination therapy versus EVL alone. Interestingly, 
combination pharmacological therapy (BB and ISMN) had a lower effect in reducing 
all-source rebleeding compared to BB alone. These results indicate that BB exert their 
beneficial effect combined with EVL, effect that may be hampered by the concomitant 
use of ISMN.  
Our study however has several limitations. i) As in every meta-analysis, the overall 
quality depends on that of the individual data. We built the final dataset of IPD after 
checking for completeness and internal consistency, and excluding those IPD with 
insufficient information, in whom it could not be obtained upon request. For these 
reasons and in order to build a robust database, we excluded from the variceal 
rebleeding analysis those patients from trials lacking individual source of bleeding 
information (18, 21). ii) The absence of uniform standard definitions and the 
insufficient information of adverse events precluded performing safety analysis. iii) The 
accuracy of conclusions in Child A is limited by the rather, but otherwise expected, low 
number of events in this population.  
Altogether, our results, while confirming results from aggregate meta-analysis, point out 
differences in response to secondary prophylaxis therapies in patients with compensated 
versus decompensated cirrhosis. In those with compensated cirrhosis, combination 
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therapy is indicated to prevent all-source rebleeding (although without an effect on 
mortality) while in those with decompensated cirrhosis in whom the key outcome is 
mortality, combination therapy, but mostly the BB component of combination therapy, 
is associated with a reduction in mortality.  The study demonstrates that EVL should not 
be used as monotherapy, as this is associated with lower overall efficacy in preventing 
rebleeding, and with increased mortality in Child B/C patients.  Current evidence does 
not support a harmful effect of BB in patients with decompensated cirrhosis but rather a 
beneficial effect.  Therefore, careful thought should be given before discontinuing BB 
(or before considering not initiating them when indicated) in patients with cirrhosis, 
particularly in those at a decompensated stage. 
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FIGURE LEGENDS 
Figure 1. Flow diagram of the individual patient data (IPD) meta-analyses 
following PRISMA guideline and recommendation.  
IPD, individual patient data; EVL, endoscopic variceal ligation; BB, non-selective beta-
blockers, PHG, portal hypertensive gastropathy. 
Figure 2. Forrest plots of overall rebleeding (top) and mortality (bottom) in trials 
comparing combination of endoscopic variceal ligation (EVL) and beta-blockers 
(BB) with either therapy alone. Diamonds represent the incidence rate ratios (IRR). 
Horizontal lines indicate the 95% CIs. Heterogeneity measured as Median Incidence 
Rate Ratios (MIRR). Comparison between Child subgroups for each outcome is shown 
by p for interaction. 
Figure 3. Survival probability according to treatment and Child class with 
combination of endoscopic variceal ligation (EVL) and beta-blockers (BB) versus 
BB alone (top) or versus EVL alone (bottom), as estimated by Kaplan-Meier.  
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Table 1. Characteristics of the 6 studies included in the meta-analyses. 
 
 
*Exclusion criteria common to all studies were: previous therapy with endoscopy or beta-blockers, bleeding from gastric varices, presence of hepatocellular 
carcinoma, portal hypertensive gastropathy bleeding, debilitating disease, TIPS, pregnancy. 
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(cont.) Table 1. Characteristics of the 6 studies included in the meta-analyses 
 
 
* Exclusion criteria common to all studies were: previous therapy with endoscopy or beta-blockers, bleeding from gastric varices, presence of hepatocellular 
carcinoma, portal hypertensive gastropathy bleeding, debilitating disease, TIPS, pregnancy. 
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Table 2. Baseline demographic, clinical and laboratory characteristics of patients 
with cirrhosis allocated to each IPD meta-analyses. 
 Endoscopic variceal 
ligation (EVL) and beta-
blockers (BB) vs. BB 
 Endoscopic variceal 
ligation (EVL) and beta-
blockers (BB) vs. EVL 








Age (years) 53.6 ± 0.9 54.1 ± 0.7  51.1 ± 0.8 50.7 ± 0.9 
Sex (male/female) 
(%) 
66/34 68/32  72/28 79/21 
Etiology (%) 
   Alcohol 
   Virus 

















Bilirubin (md/dl) 2.3 ± 0.2 2.2 ± 0.1  2.4 ± 0.1 2.5 ± 0.2 
Albumin (g/dl) 3.0 ± 0.2 3.1 ± 0.1  3.0 ± 0.2 3.0 ± 0.4 
Prothrombin ratio (%) 69 ± 14 68 ± 14  69 ± 15 67 ± 19 
Child-Pugh (%) 
   A 














Data are shown as mean±SD or as % 
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Table 3. Sensitivity analyses 
 
 


















Child A 0.46 (0.21; 1.04) 
0.024 
0.38 (0.14; 1.00) 
0.067 
Child B/C 1.35 (0.86; 2.12) 1.05 (0.64; 1.72) 
Variceal 
rebleeding 
Child A 0.32 (0.14; 0.76) 
0.009 
0.27 (0.09; 0.76) 
0.043 
Child B/C 1.23 (0.73; 2.06) 0.88 (0.53; 1.47) 
EVL and 




Child A 0.21 (0.04; 0.97) 
0.444 
0.21 (0.04; 1.03) 
0.206 
Child B/C 0.39 (0.23; 0.68) 0.62 (0.36; 1.07) 
Variceal 
rebleeding 
Child A 0.23 (0.02; 2.17) 
0.429 
0.43 (0.04; 4.98) 
0.579 
Child B/C 0.59 (0.26; 1.33) 0.89 (0.41; 1.89) 
 
a 
Sub-hazard Ratio (SHR) for the effect of combination of endoscopic variceal ligation (EVL) and 
beta-blockers (BB) versus monotherapy (BB or EVL) (as reference) 
b 
P-Value for the interaction between treatment effect and Child-Pugh groups 
c 
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